• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JCI Insight . Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody

tetano

Editor, Senior Moderator
JCI Insight


. 2024 May 22;9(10):e179726.
doi: 10.1172/jci.insight.179726. Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody

Yi-Hsuan Chang[SUP] 1 2 [/SUP], Min-Feng Hsu[SUP] 3 [/SUP], Wei-Nan Chen[SUP] 1 [/SUP], Min-Hao Wu[SUP] 3 [/SUP], Wye-Lup Kong[SUP] 4 [/SUP], Mei-Yeh Jade Lu[SUP] 4 [/SUP], Chih-Heng Huang[SUP] 5 6 7 [/SUP], Fang-Ju Chang[SUP] 1 [/SUP], Lan-Yi Chang[SUP] 3 [/SUP], Ho-Yang Tsai[SUP] 1 2 [/SUP], Chao-Ping Tung[SUP] 1 [/SUP], Jou-Hui Yu[SUP] 1 [/SUP], Yali Kuo[SUP] 8 [/SUP], Yu-Chi Chou[SUP] 8 [/SUP], Li-Yang Bai[SUP] 1 [/SUP], Yuan-Chih Chang[SUP] 3 9 [/SUP], An-Yu Chen[SUP] 5 6 [/SUP], Cheng-Cheung Chen[SUP] 5 6 [/SUP], Yi-Hua Chen[SUP] 4 [/SUP], Chun-Che Liao[SUP] 8 [/SUP], Chih-Shin Chang[SUP] 8 [/SUP], Jian-Jong Liang[SUP] 10 [/SUP], Yi-Ling Lin[SUP] 8 10 [/SUP], Takashi Angata[SUP] 2 3 [/SUP], Shang-Te Danny Hsu[SUP] 2 3 11 [/SUP], Kuo-I Lin[SUP] 1 8 [/SUP]



Affiliations
Free article Abstract

Since its emergence, SARS-CoV-2 has been continuously evolving, hampering the effectiveness of current vaccines against COVID-19. mAbs can be used to treat patients at risk of severe COVID-19. Thus, the development of broadly protective mAbs and an understanding of the underlying protective mechanisms are of great importance. Here, we isolated mAbs from donors with breakthrough infection with Omicron subvariants using a single-B cell screening platform. We identified a mAb, O5C2, which possesses broad-spectrum neutralization and antibody-dependent cell-mediated cytotoxic activities against SARS-CoV-2 variants, including EG.5.1. Single-particle analysis by cryo-electron microscopy revealed that O5C2 targeted an unusually large epitope within the receptor-binding domain of spike protein that overlapped with the angiotensin-converting enzyme 2 binding interface. Furthermore, O5C2 effectively protected against BA.5 Omicron infection in vivo by mediating changes in transcriptomes enriched in genes involved in apoptosis and interferon responses. Our findings provide insights into the development of pan-protective mAbs against SARS-CoV-2.

Keywords: Adaptive immunity; COVID-19; Immunoglobulins; Infectious disease; Structural biology.

 
Back
Top Bottom